Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed medulloblastoma~2. Standard-risk disease~3. No residual tumor greater than 1.5 cm\^2 after resection by postoperative MRI~   * No tumor in the spinal or cerebral subarachnoid space by MRI~  * No tumor in the subarachnoid space by Cerebrospinal fluid (CSF)~  * No failure to perform staging studies (spine MRI and CSF cytology) preoperatively or postoperatively~4. Must begin radiotherapy on study within 28 days after surgery~Exclusion Criteria:~1. Prior radiotherapy and anti-tumor chemotherapy other than corticosteroids are not allowed.~2. Pregnant females will not be eligible~3. Patients must begin radiotherapy on protocol within 28 days of completion of surgery. Exceptions need to be approved by the Principal Investigator.~4. Patients with the following will not be eligible:~   * \> 1.5cm3 residual tumor following resection as indicated by post-operative MRI.~  * tumor in spinal or cerebral subarachnoid space either by MRI of brain and spine~  * tumor in subarachnoid space by CSF cytology~  * failure to perform staging studies (spine MRI, CSF cytology) either pre- or post- operatively

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Study Treatment (Type: EXPERIMENTAL): All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatment is completed, all subjects will begin 9 cycles (each cycle lasts 6 weeks) of maintenance chemotherapy which will be given as 2 different drug combinations, Regimen A (Lomustine, Vincristine, and Cisplatin) and Regimen B (Cyclophosphamide, given with Mesna, and Etoposide \[IV and oral\]) which will be given in the following order: AABAABAAB (total of 54 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).